Personal information

No personal information available

Activities

Collapse all

Funding (2)

Ipilimumab with or without nivolumab for patients with relapsed/refractory classic Hodgkin lymphoma

2021-03-01 to 2024-02-28 | Grant
Lymphoma Research Foundation (New York, US)
GRANT_NUMBER:

816520
Source: check_circle
ProposalCentral

A Phase 1b trial of duvelisib and the OX40 co-stimulatory agonist PF-04518600 in relapsed/refractory marginal zone lymphoma

2019-04-01 to 2021-10-31 | Grant
Lymphoma Research Foundation (New York, US)
GRANT_NUMBER:

610166
Source: check_circle
ProposalCentral

Works (16)

Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma.

The oncologist
2020-04-10 | Journal article
DOI: 10.1634/theoncologist.2020-0040
PMID: 32275786
Source: Self-asserted source
Reid W Merryman

Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma.

Blood advances
2020-03-01 | Journal article
DOI: 10.1182/bloodadvances.2019001355
PMID: 32126141
PMC: PMC7065472
Source: Self-asserted source
Reid W Merryman

PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation.

Blood advances
2020-01-01 | Journal article
DOI: 10.1182/bloodadvances.2019000784
PMID: 31917843
PMC: PMC6960482
Source: Self-asserted source
Reid W Merryman

Novel agents and immune invasion in Hodgkin lymphoma.

Hematology. American Society of Hematology. Education Program
2019-12-01 | Journal article
DOI: 10.1182/hematology.2019000029
PMID: 31808827
Source: Self-asserted source
Reid W Merryman

PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation.

Blood
2019-04-05 | Journal article
DOI: 10.1182/blood.2019000215
PMID: 30952672
Source: Self-asserted source
Reid W Merryman

Reply to H.J.A. Adams et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2018-09-17 | Journal article
DOI: 10.1200/jco.18.00851
PMID: 30222482
Source: Self-asserted source
Reid W Merryman

Response-Adapted Therapy in Aggressive Lymphoma: Not Yet Ready for Clinical Care.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2018-05-22 | Journal article
DOI: 10.1200/jco.2018.78.9362
PMID: 29787359
Source: Self-asserted source
Reid W Merryman

Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil.

Blood
2018-05-02 | Journal article
DOI: 10.1182/blood-2018-02-811174
PMID: 29720488
Source: Self-asserted source
Reid W Merryman

Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma.

Blood advances
2017-12-12 | Journal article
DOI: 10.1182/bloodadvances.2017012534
PMID: 29296917
PMC: PMC5728646
Source: Self-asserted source
Reid W Merryman

PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD.

Blood
2017-05-03 | Journal article
DOI: 10.1182/blood-2017-01-761346
PMID: 28468799
PMC: PMC5510790
Source: Self-asserted source
Reid W Merryman

Immune Checkpoint Blockade and Hematopoietic Stem Cell Transplant.

Current hematologic malignancy reports
2017-02-01 | Journal article
DOI: 10.1007/s11899-017-0362-5
PMID: 28155012
Source: Self-asserted source
Reid W Merryman

Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma.

Blood
2017-01-10 | Journal article
DOI: 10.1182/blood-2016-09-738385
PMID: 28073785
PMC: PMC5345733
Source: Self-asserted source
Reid W Merryman

Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2016-10-24 | Journal article
DOI: 10.1200/JCO.2016.68.2740
PMID: 28034071
PMC: PMC5455688
Source: Self-asserted source
Reid W Merryman

Asparaginase-associated myelosuppression and effects on dosing of other chemotherapeutic agents in childhood acute lymphoblastic leukemia.

Pediatric blood & cancer
2012-04-24 | Journal article
DOI: 10.1002/pbc.24182
PMID: 22532399
PMC: PMC4587903
Source: Self-asserted source
Reid W Merryman

A deficiency of uPAR alters endothelial angiogenic function and cell morphology.

Vascular cell
2011-05-02 | Journal article
DOI: 10.1186/2045-824X-3-10
PMID: 21535874
PMC: PMC3105951
Source: Self-asserted source
Reid W Merryman

The state of health policy education in U.S. medical schools.

The New England journal of medicine
2011-02-23 | Journal article
DOI: 10.1056/nejmp1101603
PMID: 21345091
Source: Self-asserted source
Reid W Merryman
How many people are using ORCID?